Skip to content

Effects of "Glucose-Insulin-Potassium"

Evaluation of the effects of "Glucose-Insulin-Potassium" administration on hemodynamic parameters and cardiac indices in patients admitted to the intensive care unit

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220730055585N1
Enrollment
50
Registered
2022-08-10
Start date
2022-08-11
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hypotension, impaired hemodynamic parameters. Condition 2: Impaired cardiac indexes (heart failure). Hypotension Unspecified systolic (congestive) heart failure

Interventions

Different patients are admitted in intensive care units with different severity and etiology. The selection of patients was done based on randomization. according to the design of the study, each pati
GIK cocktail infusion (insuline 15 IU+vial Kcl15% 20 mEq+Dextrose 50% 50ml) and in diabetic patients the same cocktail but Insuline 20 IU will apply. rate of infusion will be 10 ml/h for 12 hours. Car

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients admitted in intensive care units needing cardiovascular drug support due to systemic hypotension (shock) Decreased heart performance

Exclusion criteria

Exclusion criteria: Age below 18 years old Patients who do not participate or discontinue Pregnancy Brest feeding Central nerves system and cerebrovascular disease Anemia Chronic kidney disease Active bleeding Metastatic cancer IV drug user Chronic alcohol user Acute multi organ failure Brain death

Design outcomes

Primary

MeasureTime frame
Blood pressure. Timepoint: patient's entrance time to ICU, zero time (before prescription), 1h, 6h and 12h after prescription (during infusion). Method of measurement: non invasive blood pressure - automated monitoring.;Stroke volume. Timepoint: patient's entrance time to ICU, zero time (before prescription), 1h, 6h and 12h after prescription (during infusion). Method of measurement: Ultra sonic cardiac output monitoring (USCOM).;Heart rate. Timepoint: patient's entrance time to ICU, zero time (before prescription), 1h, 6h and 12h after prescription (during infusion). Method of measurement: Monitoring device.;Systemic Vascular Resistance. Timepoint: patient's entrance time to ICU, zero time (before prescription), 1h, 6h and 12h after prescription (during infusion). Method of measurement: Ultra sonic cardiac output monitoring (USCOM).

Secondary

MeasureTime frame
Cardiac output. Timepoint: Patient's entrance time to ICU, zero time (before prescription), 1h, 6h and 12h after prescription (during infusion). Method of measurement: Ultra sonic cardiac output monitoring (USCOM).;Delivery Oxygen. Timepoint: Patient's entrance time to ICU, zero time (before prescription), 1h, 6h and 12h after prescription (during infusion). Method of measurement: Ultra sonic cardiac output monitoring (USCOM).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Jabbari

Tehran University of Medical Sciences

dr.jabbari_a@goums.ac.ir+98 21 6634 8500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026